{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T08:58:43Z","timestamp":1791536323222,"version":"4.3.4"},"reference-count":42,"publisher":"The Endocrine Society","issue":"4","license":[{"start":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T00:00:00Z","timestamp":1582070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Medical Research Council Versus Arthritis Centre for Integrated Research into Musculoskeletal Ageing","award":["MR\/R502182\/1"],"award-info":[{"award-number":["MR\/R502182\/1"]}]},{"name":"The Medical Research Council Versus Arthritis Centre for Integrated Research into Musculoskeletal Ageing","award":["R\/130188"],"award-info":[{"award-number":["R\/130188"]}]},{"name":"Osteoporosis 2000 Support Group"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Normocalcemic hyperparathyroidism (NPHPT) is characterized by persistently normal calcium levels and elevated parathyroid hormone (PTH) values, after excluding other causes of secondary hyperparathyroidism. The prevalence of the disease varies greatly and the data on the natural history of this disease are sparse and inconclusive.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The objectives of this study are to describe the prevalence of NPHPT and its natural history in a referral population and to compare the variability of serum calcium with a group of patients with primary hyperparathyroidism (PHPT).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>A retrospective study was conducted over 5 years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>The setting for this study was a metabolic bone referral center.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients<\/jats:title>\n                  <jats:p>A total of 6280 patients were referred for a bone mineral density measurement (BMD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures<\/jats:title>\n                  <jats:p>The prevalence and natural history of NPHPT and variability of calcium were the main outcome measures.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We identified NPHPT patients using data from the day of the BMD measurement. We excluded patients with low estimated glomerular filtration rate (eGFR) or vitamin D, or with no measurements available. Based on the evaluation of their medical files, we identified 11 patients with NPHPT (prevalence 0.18%). Only 4 patients had consistent normocalcemia throughout their follow-up, with only 2 also having consistently high PTH. None had consistently normal eGFR or vitamin D.<\/jats:p>\n                  <jats:p>Intermittent hypercalcemia was present in 7 of the 11 NPHPT patients. The mean adjusted calcium was found to be significantly lower in the NPHPT group compared with the PHPT group but higher than the control group. PTH was similar for NPHPT and PHPT. These 2 groups had similar variability in serum calcium.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>NPHPT patients often have episodes of hypercalcemia. We believe that NPHPT is a mild form of PHPT.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgaa084","type":"journal-article","created":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T05:29:40Z","timestamp":1582090180000},"page":"e1171-e1186","source":"Crossref","is-referenced-by-count":82,"title":["Normocalcemic Hyperparathyroidism: Study of its Prevalence and Natural History"],"prefix":"10.1210","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2204-2095","authenticated-orcid":false,"given":"Marian","family":"Schini","sequence":"first","affiliation":[{"name":"Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M","family":"Jacques","sequence":"additional","affiliation":[{"name":"School of Health and Related Research, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Oakes","sequence":"additional","affiliation":[{"name":"Sheffield Teaching Hospitals National Health Service Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola F A","family":"Peel","sequence":"additional","affiliation":[{"name":"Sheffield Teaching Hospitals National Health Service Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S","family":"Walsh","sequence":"additional","affiliation":[{"name":"Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Eastell","sequence":"additional","affiliation":[{"name":"Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2020,2,19]]},"reference":[{"issue":"2","key":"2021122209574419600_CIT0001","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1210\/jc.2008-1758","article-title":"Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop","volume":"94","author":"Eastell","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"2021122209574419600_CIT0002","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1210\/jc.2014-1414","article-title":"Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop","volume":"99","author":"Eastell","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2021122209574419600_CIT0003","doi-asserted-by":"crossref","first-page":"L27","DOI":"10.1210\/jc.2014-4065","article-title":"Letter to the editor: Thiazides are not inducers of PTH secretion: a comment on normocalcemic hyperparathyroidism","volume":"100","author":"Yacobi-Bach","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"2021122209574419600_CIT0004","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1210\/jc.2014-1415","article-title":"Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop","volume":"99","author":"Silverberg","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2021122209574419600_CIT0005","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/MED.0000000000000198","article-title":"An overview of normocalcemic primary hyperparathyroidism","volume":"22","author":"Pawlowska","year":"2015","journal-title":"Curr Opin Endocrinol Diabetes Obes."},{"issue":"3","key":"2021122209574419600_CIT0006","doi-asserted-by":"crossref","first-page":"384","DOI":"10.4158\/EP09346.OR","article-title":"Calcium, parathyroid hormone, and vitamin D in patients with primary hyperparathyroidism: normograms developed from 10 000 cases","volume":"17","author":"Norman","year":"2011","journal-title":"Endocr Pract."},{"key":"2021122209574419600_CIT0007","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/000456329603300108","article-title":"Adjustment of serum total calcium for albumin concentration: effects of non-linearity and of regression differences between laboratories","volume":"33 (Pt 1)","author":"Barth","year":"1996","journal-title":"Ann Clin Biochem."},{"key":"2021122209574419600_CIT0008","article-title":"2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","author":"KDIGO"},{"issue":"411","key":"2021122209574419600_CIT0009","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/01621459.1990.10474920","article-title":"Unmasking multivariate outliers and leverage points","volume":"85","author":"Rousseeuw","year":"1990","journal-title":"Journal of the American Statistical Association"},{"issue":"1","key":"2021122209574419600_CIT0010","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/wics.19","article-title":"Minimum volume ellipsoid","volume":"1","author":"Van Aelst","year":"2009","journal-title":"Wiley Interdisciplinary Reviews: Computational Statistics"},{"issue":"6","key":"2021122209574419600_CIT0011","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/cen.12732","article-title":"Normocalcaemic hypoparathyroidism: prevalence and effect on bone status in older women. The OPUS study","volume":"82","author":"Palermo","year":"2015","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"7059","key":"2021122209574419600_CIT0012","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/bmj.313.7059.744","article-title":"Measurement error","volume":"313","author":"Bland","year":"1996","journal-title":"Bmj."},{"issue":"5","key":"2021122209574419600_CIT0013","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/ageing\/afu093","article-title":"National osteoporosis society vitamin D guideline summary","volume":"43","author":"Aspray","year":"2014","journal-title":"Age Ageing."},{"issue":"2","key":"2021122209574419600_CIT0014","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.semnephrol.2008.01.005","article-title":"New insights into the pathogenesis of idiopathic hypercalciuria","volume":"28","author":"Worcester","year":"2008","journal-title":"Semin Nephrol."},{"issue":"5","key":"2021122209574419600_CIT0015","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1590\/S0004-27302011000500003","article-title":"Normocalcemic primary hyperparathyroidism in clinical practice: an indolent condition or a silent threat?","volume":"55","author":"Marques","year":"2011","journal-title":"Arq Bras Endocrinol Metabol."},{"issue":"3","key":"2021122209574419600_CIT0016","doi-asserted-by":"crossref","first-page":"294","DOI":"10.4158\/EP15704.OR","article-title":"Primary hyperparathyroidism, with a focus on management of the normocalcemic form: to treat or not to treat?","volume":"22","author":"\u0160iprov\u00e1","year":"2016","journal-title":"Endocr Pract."},{"issue":"3","key":"2021122209574419600_CIT0017","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/cen.12569","article-title":"Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers","volume":"82","author":"Berger","year":"2015","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"7","key":"2021122209574419600_CIT0018","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1210\/jc.2013-1300","article-title":"Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations","volume":"98","author":"Cusano","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021122209574419600_CIT0019","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s12020-012-9694-z","article-title":"Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred postmenopausal women","volume":"42","author":"Garc\u00eda-Mart\u00edn","year":"2012","journal-title":"Endocrine."},{"issue":"2","key":"2021122209574419600_CIT0020","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/cen.12819","article-title":"Normocalcaemic, vitamin D-sufficient hyperparathyroidism - high prevalence and low morbidity in the general population: A long-term follow-up study, the WHO MONICA project, Gothenburg, Sweden","volume":"83","author":"Kontogeorgos","year":"2015","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"3","key":"2021122209574419600_CIT0021","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0039-6060(97)90357-3","article-title":"Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women","volume":"121","author":"Lundgren","year":"1997","journal-title":"Surgery."},{"issue":"4","key":"2021122209574419600_CIT0022","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1055\/a-0859-1020","article-title":"Normocalcemic primary hyperparathyroidism in adults without a history of nephrolithiasis or fractures: a prospective study","volume":"51","author":"Ros\u00e1rio","year":"2019","journal-title":"Horm Metab Res."},{"issue":"3","key":"2021122209574419600_CIT0023","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1530\/EC-15-0030","article-title":"Normocalcemic primary hyperparathyroidism: a survey in a small village of Southern Italy","volume":"4","author":"Vignali","year":"2015","journal-title":"Endocr Connect."},{"issue":"11","key":"2021122209574419600_CIT0024","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1210\/jc.2005-2825","article-title":"Changes in insulin sensitivity and glucose and bone metabolism over time in patients with asymptomatic primary hyperparathyroidism","volume":"91","author":"Ayturk","year":"2006","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"2021122209574419600_CIT0025","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.amjmed.2004.06.037","article-title":"Characterization of normocalcemic primary hyperparathyroidism","volume":"117","author":"Tordjman","year":"2004","journal-title":"Am J Med."},{"issue":"3","key":"2021122209574419600_CIT0026","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s12020-014-0263-5","article-title":"Investigation of glucose intolerance in patients with normocalcemic primary hyperparathyroidism: 4-year follow-up","volume":"47","author":"Diri","year":"2014","journal-title":"Endocrine."},{"issue":"11","key":"2021122209574419600_CIT0027","doi-asserted-by":"crossref","first-page":"5348","DOI":"10.1210\/jc.2003-031014","article-title":"\u201cIncipient\u201d primary hyperparathyroidism: a \u201cforme fruste\u201d of an old disease","volume":"88","author":"Silverberg","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2021122209574419600_CIT0028","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1245\/s10434-018-6998-0","article-title":"Biochemical and Skeletal Outcomes of Parathyroidectomy for Normocalcemic (Incipient) Primary Hyperparathyroidism","volume":"26","author":"Sho","year":"2019","journal-title":"Ann Surg Oncol."},{"issue":"8","key":"2021122209574419600_CIT0029","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1210\/jc.2006-2802","article-title":"Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype","volume":"92","author":"Lowe","year":"2007","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021122209574419600_CIT0030","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1530\/EJE-19-0316","article-title":"MANAGEMENT OF ENDOCRINE DISEASE: Unmet therapeutic, educational and scientific needs in parathyroid disorders","volume":"181","author":"Bollerslev","year":"2019","journal-title":"Eur J Endocrinol."},{"issue":"8","key":"2021122209574419600_CIT0031","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1210\/jc.2013-1518","article-title":"Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism","volume":"98","author":"Koumakis","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021122209574419600_CIT0032","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.surg.2016.08.054","article-title":"Differences in single gland and multigland disease are seen in low biochemical profile primary hyperparathyroidism","volume":"161","author":"Lim","year":"2017","journal-title":"Surgery."},{"issue":"3","key":"2021122209574419600_CIT0033","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00423-018-1659-0","article-title":"Is parathyroidectomy safe and effective in patients with normocalcemic primary hyperparathyroidism?","volume":"403","author":"Traini","year":"2018","journal-title":"Langenbecks Arch Surg."},{"issue":"1","key":"2021122209574419600_CIT0034","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.surg.2019.06.043","article-title":"Normocalcemic hyperparathyroidism: a collaborative endocrine surgery quality improvement program analysis","volume":"167","author":"Pandian","year":"2020","journal-title":"Surgery."},{"issue":"4","key":"2021122209574419600_CIT0035","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1007\/s00268-018-4512-2","article-title":"Classic primary hyperparathyroidism versus normocalcemic and normohormonal variants: do they really differ?","volume":"42","author":"Kiriakopoulos","year":"2018","journal-title":"World J Surg."},{"issue":"1","key":"2021122209574419600_CIT0036","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.amjsurg.2019.10.032","article-title":"Comparative prospective study on the presentation of normocalcemic primary hyperparathyroidism. Is it more aggressive than the hypercalcemic form?","volume":"219","author":"G\u00f3mez-Ram\u00edrez","year":"2020","journal-title":"Am J Surg."},{"key":"2021122209574419600_CIT0037","doi-asserted-by":"crossref","first-page":"2150159","DOI":"10.1155\/2019\/2150159","article-title":"Do symptoms and serum calcium levels affect the results of surgical treatment of primary hyperparathyroidism?","volume":"2019","author":"Yu","year":"2019","journal-title":"Biomed Res Int."},{"issue":"10","key":"2021122209574419600_CIT0038","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1210\/jc.2002-021404","article-title":"Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone","volume":"88","author":"Maruani","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021122209574419600_CIT0039","first-page":"163","article-title":"Clinical expression of calcium sensing receptor polymorphism (A986S) in normocalcemic and asymptomatic hyperparathyroidism","volume":"48","author":"D\u00edaz-Soto","year":"2016","journal-title":"Horm Metab Res."},{"issue":"10","key":"2021122209574419600_CIT0040","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1210\/jc.2014-1413","article-title":"Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop","volume":"99","author":"Bilezikian","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2021122209574419600_CIT0041","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1210\/jc.2014-4370","article-title":"Brief report: does PTH increase with age, independent of 25- hydroxyvitamin D, phosphate, renal function, and ionized calcium?","volume":"100","author":"Carrivick","year":"2015","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"issue":"1","key":"2021122209574419600_CIT0042","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1210\/jc.2012-2499","article-title":"Further insights into the pathogenesis of primary hyperparathyroidism: a nested case-control study","volume":"98","author":"Rejnmark","year":"2013","journal-title":"J Clin Endocrinol Metab."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaa084\/32519656\/dgaa084.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/4\/e1171\/41859506\/jcem_105_4_e1171.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/4\/e1171\/41859506\/jcem_105_4_e1171.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T18:02:01Z","timestamp":1640196121000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/105\/4\/e1171\/5740224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,19]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,2,19]]},"published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaa084","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,4]]},"published":{"date-parts":[[2020,2,19]]}}}